Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|October 10, 2019
Outcome of twin-to-twin transfusion syndrome in monochorionic monoamniotic twin pregnancy: systematic review and meta-analysisD Murgano, A Khalil, F Prefumo, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Leukemia|June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyF Cavallo, S Bringhen, G Milone, et al.
Leukemia|July 17, 2014
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalS Ferrero, M Ladetto, D Drandi, et al.
Leukemia|November 14, 2013
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II TrialA Cortelezzi, M Sciumè, A M Liberati, et al.
Blood Cancer Journal|November 26, 2013
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II studyM Offidani, L Corvatta, L Maracci, et al.
Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Leukemia|December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysisF Gay, S Oliva, M T Petrucci, et al.
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
The Lancet. Haematology|May 13, 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trialMeletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, et al.
Pageof 21